Insights
Search Results
Client Highlights
5.29.24
Wilson Sonsini Advises Radar Therapeutics on IP Matters Related to $13.4 Million Seed Funding
On May 23, 2024, Radar Therapeutics, a biotech company developing smart programmable medicines, announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC, and other investors. Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related to the transaction.
Alerts
12.22.23
Draft Guidance Puts March-In Authority Pursuant to Bayh-Dole in the News Once Again
On December 8, 2023, the National Institute of Standards and Technology (NIST) released the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (guidance) to the public for comment. The comment period ends February 6, 2024. The information received in response to the guidance will inform NIST and the Interagency Working Group for Bayh-Dole (IAWGBD) in developing a final framework document that may be used by an agency when deciding whether to exercise its march-in authority. While the guidance is the first federal framework specifying that price can be a factor in considering whether the government may exercise its march-in authority pursuant to 35 U.S.C. 200 et seq. (Bayh-Dole), this is not the first time that attention has been drawn to the government’s march-in authority.
Newsletters
6.18.19
The Life Sciences Report: Summer 2019
June 18, 2019
The Summer 2019 edition of The Life Sciences Report features articles about navigating the U.S. healthcare regulatory landscape for wearable devices and automation in legal practice. In addition, the publication includes an interview with Katherine Ku, the firm’s chief licensing advisor, and information about Matthew J. Meyer, the new chief client corporate development advisor to the firm's life sciences practice.